8-K: Nuwellis Reports Fourth Quarter and Full Year 2024 Financial Results, Consumables Utilization Up 21%

Nuwellis, Inc. announced its Q4 and full-year 2024 financial results, highlighting a CMS payment increase and a 21% growth in consumables utilization despite a revenue decrease.

Summary

• Nuwellis, Inc. reported a 9% decrease in revenue for the fourth quarter of 2024, totaling $2.3 million.
• This decrease is attributed to lower US console and international sales, offset by a 21% increase in consumables utilization.
• The company's gross margin improved to 58.4% compared to 54.4% in the prior year quarter, driven by higher manufacturing volumes and lower fixed overhead.
• SG&A expenses decreased to $2.9 million due to efficiency initiatives.
• R&D expenses also decreased to $831,000 due to reduced consulting fees and compensation expenses.
• The operating loss for the quarter decreased to $2.4 million from $3.6 million in the prior year.
• Net loss attributable to common shareholders was $1.5 million, or $0.44 per share, compared to $7.9 million, or $54.48 per share, in the prior year.
• The company had no debt and $5.1 million in cash and cash equivalents as of December 31, 2024.
• For the full year, Nuwellis reported revenue of $8.74 million, a slight decrease from $8.864 million in the prior year.
• The company experienced a full year operating cost reduction of $5.9 million, or 26%, compared to the prior year.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to improved profitability metrics, strong consumables growth, and favorable CMS reimbursement changes, despite a slight revenue decrease. The company's focus on growth and market penetration in 2025 also contributes to the positive outlook.

Positives

• CMS payment increase for Aquadex Ultrafiltration Therapy enhances outpatient opportunities.
• Clinical data supports Aquadex effectiveness in reducing heart failure events.
• Operating cost reductions improved profitability.
• Consumables utilization growth indicates increased product adoption.
• Critical Care revenue growth demonstrates strength in a key customer segment.
• Gross margin improvement reflects efficient manufacturing.
• The company had no debt as of December 31, 2024.

Negatives

• Revenue decreased by 9% in the fourth quarter of 2024 compared to the prior year quarter.
• The revenue decrease is attributable to a decrease in US console sales and international sales.
• A voluntary recall of specific lots of blood circuit units resulted in a $150,000 non-recurring expense in December 2024.

Risks

• The company's ability to execute its commercialization strategy is subject to risks.
• Nuwellis may be unable to raise sufficient funds necessary for its anticipated operations.
• Market and physician acceptance of Nuwellis' products may not increase as expected.
• Competitive product offerings could impact Nuwellis' market share.
• Intellectual property protection is crucial for maintaining a competitive advantage.

Future Outlook

Nuwellis expects to drive progress on its growth agenda in 2025, supported by increasing awareness of clinical evidence, favorable CMS reimbursement changes, and continued market penetration.

Management Comments

• John Erb, Chairman of the Board and interim CEO of Nuwellis, stated that the company's commitment to making Aquadex the standard of care for fluid overload resulted in consumables utilization growth and increased revenue in Critical Care.

Industry Context

The announcement highlights Nuwellis' efforts to capitalize on the growing need for effective fluid management solutions, particularly in heart failure patients. The CMS reimbursement increase is a positive development that could drive adoption in the outpatient setting. Competitors in the fluid management space include companies offering diuretic therapies and other ultrafiltration systems.

Comparison to Industry Standards

• The 21% growth in consumables utilization is a positive sign, suggesting increasing adoption of the Aquadex system.
• Compared to companies like Baxter and Fresenius Medical Care, which offer a range of dialysis and fluid management products, Nuwellis is more focused on the specific niche of ultrafiltration for fluid overload.
• The CMS reimbursement increase positions Nuwellis favorably compared to companies relying solely on traditional diuretic therapies, as it provides a financial incentive for outpatient use of Aquadex.

Management Changes

Stakeholder Impact

• Shareholders may be encouraged by the improved profitability and growth prospects.
• Employees may benefit from the company's focus on growth and market penetration.
• Customers (healthcare providers and patients) may benefit from the increased availability and affordability of Aquadex therapy due to the CMS reimbursement increase.
• Suppliers may see increased demand for consumables as Aquadex adoption grows.

Next Steps

• The company will focus on driving progress on its growth agenda in 2025.
• Nuwellis will continue to increase awareness of the clinical evidence for the Aquadex system.
• The company will capitalize on the favorable change to CMS reimbursement to drive new expansion opportunities in the outpatient setting.
• Nuwellis will focus on fueling a steady cadence of new outpatient account wins and continued market penetration.

Key Dates